Helicobacter pylori screening: options and challenges. (2nd April 2016)

• Record Type: Journal Article
• Authors: Venerito, Marino; Goni, Elisabetta; Malfertheiner, Peter
• Is Part Of: Expert review of gastroenterology & hepatology. Volume 10:Number 4(2016)
• Page Start: 497
• Page End: 503
• Publication Date: 2016-04-02
• Subjects: Helicobacter pylori -- screening -- prevention -- gastric cancer -- peptic ulcer disease -- non-steroidal anti-inflammatory drugs -- vaccine; Gastroenterology -- Periodicals; Liver -- Diseases -- Periodicals; 616.3
• DOI: 10.1586/17474124.2016.1126507
• Languages: English
• ISSNs: 1747-4124

Abstract

ABSTRACT: Helicobacter pylori gastritis is the most frequent infectious disease in the gastrointestinal tract. Clinical sequelae of the infection including peptic ulcer disease, sporadic gastric cancer (GC) and primary B-cell gastric lymphoma (MALT-lymphoma) may develop in up to 20% of the infected individuals. The H. pylori screen-and-treat strategy is addressed to members of communities with high GC incidence, and first-degree relatives of GC patients. For primary GC prevention, H. pylori screen-and-treat is most effective in patients without precancerous conditions. In populations at moderate risk, strategies for GC prevention need to be explored. A special clinical scenario for primary and secondary prevention of H. pylori related benign complications are patients on non-steroidal anti-inflammatory drugs and low-dose aspirin. Vaccination represents another option for eliminating H. pylori infection in the population and a new H. pylori vaccine has shown promising results. However, long-term effects with the use of vaccine are not available.